{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:24Z","timestamp":1777870344161,"version":"3.51.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-021-01183-y","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T19:04:16Z","timestamp":1643310256000},"page":"1789-1795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is the failure of recent trials on withdrawal of calcineurin inhibitors due to inadequate mycophenolic acid dosing?"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8658-8735","authenticated-orcid":false,"given":"Rachel","family":"Hellemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-9199","authenticated-orcid":false,"given":"Daniel","family":"Abramowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"issue":"12","key":"1183_CR1","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1681\/ASN.2014121234","volume":"26","author":"DE Hricik","year":"2015","unstructured":"Hricik DE, Formica RN, Nickerson P et al (2015) Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol 26(12):3114\u20133122","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1183_CR2","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1111\/ajt.13946","volume":"16","author":"E Dugast","year":"2016","unstructured":"Dugast E, Soulillou JP, Foucher Y et al (2016) Failure of calcineurin inhibitor (Tacrolimus) weaning randomized trial in long-term stable kidney transplant recipients. Am J Transplant 16(11):3255\u20133261","journal-title":"Am J Transplant"},{"issue":"5","key":"1183_CR3","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/ajt.14109","volume":"17","author":"P Gatault","year":"2017","unstructured":"Gatault P, Kamar N, B\u00fcchler M et al (2017) Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study. Am J Transplant 17(5):1370\u20131379","journal-title":"Am J Transplant"},{"issue":"9","key":"1183_CR4","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1097\/00007890-200105150-00017","volume":"71","author":"F Vincenti","year":"2001","unstructured":"Vincenti F, Ramos E, Brattstrom C et al (2001) Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71(9):1282\u20131287","journal-title":"Transplantation"},{"issue":"5","key":"1183_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1097\/01.ASN.0000013298.11876.BF","volume":"13","author":"PJH Smak Gregoor","year":"2002","unstructured":"Smak Gregoor PJH, de S\u00e9vaux RGL, Ligtenberg G et al (2002) Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 13(5):1365\u20131373","journal-title":"J Am Soc Nephrol"},{"key":"1183_CR6","doi-asserted-by":"crossref","unstructured":"Schnuelle P, Homan van der Heide J, Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13(2):536\u2013543 (2002)","DOI":"10.1681\/ASN.V132536"},{"issue":"8","key":"1183_CR7","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1681\/ASN.2005030312","volume":"16","author":"M Hazzan","year":"2005","unstructured":"Hazzan M, Labalette M, Copin MC et al (2005) Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 16(8):2509\u20132516","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1183_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1600-6143.2006.01645.x","volume":"7","author":"H Ekberg","year":"2007","unstructured":"Ekberg H, Griny\u00f3 J, Nashan B et al (2007) Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 7(3):560\u2013570","journal-title":"Am J Transplant"},{"issue":"12","key":"1183_CR9","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/00007890-200212270-00015","volume":"74","author":"D Abramowicz","year":"2002","unstructured":"Abramowicz D, Manas D, Lao M et al (2002) Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 74(12):1725\u20131734","journal-title":"Transplantation"},{"issue":"7","key":"1183_CR10","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1681\/ASN.2004100844","volume":"16","author":"D Abramowicz","year":"2005","unstructured":"Abramowicz D, Rial MDC, Vitko S et al (2005) Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 16(7):2234\u20132240","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1183_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RES Bullingham","year":"1998","unstructured":"Bullingham RES, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34(6):429\u2013455","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1183_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1034\/j.1600-6143.2003.00079.x","volume":"3","author":"LM Shaw","year":"2003","unstructured":"Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL (2003) Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3(5):534\u2013542","journal-title":"Am J Transplant"},{"issue":"2","key":"1183_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","volume":"68","author":"T van Gelder","year":"1999","unstructured":"van Gelder T, Hilbrands LB, Vanrenterghem Y et al (1999) A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68(2):261\u2013266","journal-title":"Transplantation"},{"issue":"11","key":"1183_CR14","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","volume":"7","author":"Y le Meur","year":"2007","unstructured":"le Meur Y, B\u00fcchler M, Thierry A et al (2007) Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 7(11):2496\u20132503","journal-title":"Am J Transplant"},{"issue":"2","key":"1183_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2215\/CJN.07111009","volume":"5","author":"DRJ Kuypers","year":"2010","unstructured":"Kuypers DRJ, le Meur Y, Cantarovich M et al (2010) Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 5(2):341\u2013358","journal-title":"Clin J Am Soc Nephrol"},{"key":"1183_CR16","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 Suppl 3:S1\u2013S155","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"issue":"2","key":"1183_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA et al (2021) Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit 43(2):150\u2013200","journal-title":"Ther Drug Monit"},{"issue":"9","key":"1183_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/TP.0b013e31824ad60a","volume":"93","author":"JS Mourer","year":"2012","unstructured":"Mourer JS, den Hartigh J, van Zwet EW, Mallat MJK, Dubbeld J, de Fijter JW (2012) Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation 93(9):887\u2013894","journal-title":"Transplantation"},{"issue":"2","key":"1183_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","volume":"28","author":"T van Gelder","year":"2006","unstructured":"van Gelder T, Le Meur Y, Shaw LM et al (2006) Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28(2):145\u2013154","journal-title":"Ther Drug Monit"},{"issue":"12","key":"1183_CR20","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1111\/bcp.13755","volume":"84","author":"TC Zwart","year":"2018","unstructured":"Zwart TC, Gokoel SRM, van der Boog PJM et al (2018) Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device. Br J Clin Pharmacol 84(12):2889\u20132902","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1183_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/TP.0b013e318186f98a","volume":"86","author":"T van Gelder","year":"2008","unstructured":"van Gelder T, Silva HT, de Fijter JW et al (2008) Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86(8):1043\u20131051","journal-title":"Transplantation"},{"issue":"5","key":"1183_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/FTD.0b013e31818752d9","volume":"30","author":"TL Weber","year":"2008","unstructured":"Weber TL, Hoecker B, Armstrong VW, Oellerich M, T\u00f6nshoff B (2008) Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. Ther Drug Monit 30(5):570\u2013575","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1183_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/FTD.0b013e31821633a6","volume":"33","author":"F Saint-Marcoux","year":"2011","unstructured":"Saint-Marcoux F, Vandierdonck S, Pr\u00e9maud A, Debord J, Rousseau A, Marquet P (2011) Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit 33(3):285\u2013294","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1183_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/ASN.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20(5):1103\u20131112","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1183_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/TP.0b013e318223d7f3","volume":"92","author":"K Budde","year":"2011","unstructured":"Budde K, Tedesco-Silva H, Arns W et al (2011) Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation 92(3):321\u2013327","journal-title":"Transplantation"},{"issue":"3","key":"1183_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","volume":"10","author":"F Vincenti","year":"2010","unstructured":"Vincenti F, Charpentier B, Vanrenterghem Y et al (2010) A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 10(3):535\u2013546","journal-title":"Am J Transplant"},{"issue":"4","key":"1183_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJMoa1506027","volume":"374","author":"F Vincenti","year":"2016","unstructured":"Vincenti F, Rostaing L, Grinyo J et al (2016) Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 374(4):333\u2013343","journal-title":"N Engl J Med"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-021-01183-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-021-01183-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:26Z","timestamp":1777564466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/7\/1789\/8325616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1007\/s40620-021-01183-y","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"2 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The results presented in this paper have not been published previously in whole or part, except in abstract format. There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}